Habermann TM - Search Results

1

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS. Hong F, et al. Among authors: habermann tm. Ann Oncol. 2014 Mar;25(3):669-674. doi: 10.1093/annonc/mdt594. Ann Oncol. 2014. PMID: 24567515 Free PMC article. Clinical Trial.

2

Management of stage IE primary gastric lymphoma.

Durr ED, Bonner JA, Strickler JG, Martenson JA, Chen MG, Habermann TM, Donohue JH, Earle JD, Grill JP. Durr ED, et al. Among authors: habermann tm. Acta Haematol. 1995;94(2):59-68. doi: 10.1159/000203975. Acta Haematol. 1995. PMID: 7484014

3

Treatment of stage IE primary lymphoma of bone.

Fairbanks RK, Bonner JA, Inwards CY, Strickler JG, Habermann TM, Unni KK, Su J. Fairbanks RK, et al. Among authors: habermann tm. Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):363-72. doi: 10.1016/0360-3016(94)90059-0. Int J Radiat Oncol Biol Phys. 1994. PMID: 8276651

4

S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma.

Witzig TE, Habermann TM, Kurtin PJ, Schroeder G, Stenson MJ, Greipp PR. Witzig TE, et al. Among authors: habermann tm. Cancer. 1995 Sep 15;76(6):1059-64. doi: 10.1002/1097-0142(19950915)76:6<1059::aid-cncr2820760621>3.0.co;2-e. Cancer. 1995. PMID: 8625208

5

Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.

Gordon LI, Anderson J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P. Gordon LI, et al. Among authors: habermann tm. J Clin Oncol. 1996 Apr;14(4):1275-81. doi: 10.1200/JCO.1996.14.4.1275. J Clin Oncol. 1996. PMID: 8648384 Clinical Trial.

6

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.

Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, Inwards DJ, Colgan JP. Ansell SM, et al. Among authors: habermann tm. J Clin Oncol. 1997 Jun;15(6):2296-301. doi: 10.1200/JCO.1997.15.6.2296. J Clin Oncol. 1997. PMID: 9196143

7

Primary pulmonary lymphoma.

Habermann TM, Ryu JH, Inwards DJ, Kurtin PJ. Habermann TM, et al. Semin Oncol. 1999 Jun;26(3):307-15. Semin Oncol. 1999. PMID: 10375087 Review.

8

Primary thyroid lymphoma.

Ansell SM, Grant CS, Habermann TM. Ansell SM, et al. Among authors: habermann tm. Semin Oncol. 1999 Jun;26(3):316-23. Semin Oncol. 1999. PMID: 10375088 Review.

9

Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index.

Ansell SM, Kurtin PJ, Stenson M, Habermann TM, Greipp PR, Therneau TM, Witzig TE. Ansell SM, et al. Among authors: habermann tm. Leuk Lymphoma. 1999 Aug;34(5-6):529-37. doi: 10.3109/10428199909058480. Leuk Lymphoma. 1999. PMID: 10492076

10

Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone.

O'Neill BP, Habermann TM, Witzig TE, Rodriguez M. O'Neill BP, et al. Among authors: habermann tm. Med Oncol. 1999 Sep;16(3):211-5. doi: 10.1007/BF02906134. Med Oncol. 1999. PMID: 10523802

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

470 results

Search Page

Filters